Café

© 2026 Longbridge｜Terms of Service Privacy Policy

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Unusual Whales

May 12, 2026 at 06:31 AM

Enrollment for the registrational SAFEGUARD trial of SAB-142 is ongoing with site activation continuing. The trial is expected to be completed by the end of 2026. Topline data from the trial is anticipated to be available in the second half of 2027.

Source: Unusual Whales The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Related Stocks

SAB Biotherapeutics

USSABS

-2.08%

SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM)

USSABSW

Direxion S&P Biotech Bull 3X

USLABU

LongbridgeAI